With the field of brain-computer interface (BCI) technologies growing increasingly competitive, Precision Neuroscience has emerged as a sigificant contender in the race to unite human minds with machines.
A four-year-old company, Precision Neuroscience announced on April 17 that its core brain implant system had received approval from the U.S. Food and Drug Administration (FDA) for commerical use and limited implantation uses. According to the company’s announcement, this marks the first full regulatory clearance granted to a wireless BCI.
This milestone highlights the company’s rapid technological advancement, drawing attention from rivals such as Elon Musk’s Neuralink and Synchron, backed by Amazon founder Jeff Bezos and Microsoft co-founder Bill Gates.
The FDA approval pertains to Precision’s Layer 7 Cortical Interface, a sophisticated microelectrode array used to decode neural signals and translate them into commands for external technologies. The FDA’s clearance allows Precision to implant the device in patients for up to 30 days—marking the first time in history a BCI system has received such approval for long-term use in a clinical setting.
“This is a foundational moment for Precision,” said Dr. Benjamin Rapoport, Precision’s co-founder and chief science officer. Rapoport, who also helped co-found Neuralink, left that company the following year after its founding.
The Layer 7 Cortical Interface features an ultra-thin microelectrode array—thinner than a human hair—that adheres to the brain’s surface without causing damage. Resembling a strip of yellow Scotch tape, the array is composed of 1,024 electrodes designed to record, monitor, and stimulate electrical activity on the brain’s surface.
The FDA approval will enable surgeons to use the system during brain surgeries to map brain signals, a crucial step in advancing BCI technology. However, this is not the company’s ultimate goal for the device, but it does present an immediate opportunity to collect critical data while generating early revenue.
To date, Precision Neuroscience has temporarily implanted the Layer 7 device in 37 patients, with some cases observed at Mount Sinai Hospital in New York. Until now, the implants were used for shorter periods during ongoing brain surgeries unrelated to BCI research. With the FDA’s green light, the company can now collect data over extended periods, further advancing the development of future brain-computer interface systems.
Dr. Rapoport explained that the new clearance will allow Precision to collect high-quality data, which will be pivotal as the company works toward its long-term goal: developing a brain implant system that can help paralyzed patients restore lost functions such as movement and speech.
With competition in the BCI sector intensifying, Precision Neuroscience’s FDA approval could position the company at the forefront of the industry, rivaling Neuralink and other tech giants. As neurotech innovations continue to evolve, Precision’s work could play a crucial role in transforming the lives of individuals with paralysis, offering them a potential pathway to regain independence and improve their quality of life.
Meanwhile, companies like Neuralink continue to perform well, even as political shifts in the U.S. have introduced new uncertainties. Since the Trump administration’s return to office in January, drastic cuts to federal employees were made in February, including layoffs within the U.S. Food and Drug Administration—some of whom were connected to the review of Neuralink’s technologies. This political turbulence has coincided with a growing exodus of American postgraduate and PhD students and scientists relocating to Canada and other countries worldwide.
Despite the political uncertainty impacting the broader scientific community, advancements in BCI technology are not slowing down—in fact, they appear to be accelerating.
Chrissy Newton is a PR professional and founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on The Debrief’s YouTube Channel on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com.